Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Alabama for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Alabama only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Alabama (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Heather Brody (NPI 1013301563)

Field	Value
Entity Type	Individual
Organization	Heather Brody
Address	180 Cox Creek Pkwy S Ste B
City	Florence
State	AL
ZIP	35630
Taxonomy	Hematology & Oncology Physician
NPI Enumerated	March 23, 2015

Payer Source	Total Paid
Medicare	$3.1M
Medicaid	$0

Key Findings

Medicare revenue is highly concentrated: this provider reports Total Medicare revenue of $3.1M and the precomputed top 3 Medicare codes (J9271, Q5127, J0897) account for 83.8% of that Medicare revenue. The single code J9271 alone represents $2.1M revenue (71.2% of Medicare revenue), demonstrating extreme concentration in a very small set of services.

The code mix indicates a dedicated oncology infusion practice centered on high-cost immunotherapy and biologics: J9271 (pembrolizumab) is the dominant revenue driver, supported by high volumes of pegfilgrastim biosimilar Q5127 (864 claims, $233.3K revenue, 7.9%) and denosumab J0897 (7.7K claims, $138.2K revenue, 4.7%). Chemotherapy administration codes such as 96413 (686 claims, $61.7K, 2.1%) and multiple infusion/IV administration add-ons (96375, 96365, 96417) also appear in the top codes, which is consistent with an infusion-centric outpatient oncology service line.

This provider is a national outlier for pembrolizumab usage: J9271 is reported as 49K claims, $43 avg paid/claim, $2.1M revenue and it ranks #18 of 1841 providers nationally (99th percentile; extreme outlier, far above typical national volume for this code). That national standing indicates the provider is an unusually large dispenser of this immunotherapy relative to peers and is a major participant nationally for this specific drug.

The practice also shows unusually high outpatient visit volume relative to national peers: 99214 appears with 1.5K claims, $91 avg paid/claim, $134K revenue and ranks #3806 of 479517 providers nationally (99th percentile; extreme outlier, far above typical national volume for this code). High E/M volume paired with heavy infusion billing suggests substantial clinic throughput and regular follow-up care accompanying infusion services.

Biosimilar growth and supportive-care use are notable competitive signals: Q5127 (pegfilgrastim-fpgk) ranks #3 of 30 providers nationally (93th percentile; notably above typical national volume) with $233.3K revenue, indicating the provider is an early or heavy adopter of specific biosimilar pegfilgrastim products. That pattern, together with sizable volumes of agents such as J1437 (ferric derisomaltose) and J1750 (iron dextran), is consistent with integrated supportive care alongside oncology treatment.

Operationally, the practice performs substantial lab and phlebotomy services to support infusions: 80053 (CMP) shows 2.3K claims, $10 avg paid/claim, $22.8K revenue and 85025 (CBC) shows 2.4K claims, $8 avg paid/claim, $19K revenue, while 36415 (venipuncture) shows 2.3K claims, $8 avg paid/claim, $18.5K revenue. These volumes are consistent with in‑office monitoring and frequent lab surveillance required for systemic cancer therapies.

Payer mix is effectively single‑payer Medicare: the profile shows Total Medicare revenue of $3.1M and explicitly notes no Medicaid billing on file, so the provider’s reported billed activity is concentrated entirely in Medicare. This means Medicaid-driven network or reimbursement dynamics are not evident in the available claims data.

The provider has an established enrollment history with an NPI enumerated on 2015-03-23 (~11 years ago), and the combination of long tenure plus concentrated, high-volume Medicare billing (notably extreme outlier ranks for J9271 and 99214 and notably above-typical ranks for 96413 and 96375) suggests a mature, high-throughput oncology infusion practice that is operating well above typical peer volumes for several specialized oncology drugs and related services.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

80 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J9271	Injection, pembrolizumab, 1 mg	49,000	$40	$2.1M
Q5127	Injection, pegfilgrastim-fpgk (stimufend), biosimilar, 0.5 mg	860	$270	$233.3K
J0897	Injection, denosumab, 1 mg	7,680	$20	$138.2K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	1,470	$90	$134K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	690	$90	$61.7K
J1437	Injection, ferric derisomaltose, 10 mg	2,300	$20	$39.1K
Q5108	Injection, pegfilgrastim-jmdb (fulphila), biosimilar, 0.5 mg	360	$100	$36K
J1454	Injection, fosnetupitant 235 mg and palonosetron 0.25 mg	90	$320	$28.5K
80053	The lab analyst performs a comprehensive metabolic panel, or CMP test in which he measures the blood level of 14 chemicals the code descriptor lists for the panel.	2,280	$10	$22.8K
85025	A complete blood count (better known as a CBC) is a blood test request by a doctor that provides detailed information about various types of cells in a patient's blood. Usually a pathologist or a…	2,380	$10	$19K

Showing 1–10 of 80

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 80 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Alabama Distribution

Heather Brody — 6 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Alabama

Full comparison — all codes billed, vs. state median

80 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J9271	2	30	19,900	$40	$827.2K
Q5127	3	20	590	$270	$165.7K
J0897	41	200	3,120	$20	$97.7K
J1437	27	40	3,000	$20	$59.1K
Q5108	5	10	370	$100	$38.1K
J1454	12	20	90	$340	$33.7K
J0881	22	30	7,720	$1	$24.1K
96413	8	150	150	$90	$20.2K
99214	48	7,330	120	$80	$16.8K
82306	258	340	60	$30	$16K

Showing 1–10 of 80

Related Providers

Other providers that share a Tax Identification Number (TIN) with Heather Brody, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
John Waples	AL	Medical Oncology Physician	$9.6M	$0
Marshall Schreeder	AL	Medical Oncology Physician	$3.5M	$0
Jorge Diaz	AL	Hematology & Oncology Physician	$2.6M	$0
Naveen Lobo	AL	Medical Oncology Physician	$2.4M	$0
Ali Hachem	AL	Hematology & Oncology Physician	$2.3M	$0
Daniel Schreeder	AL	Hematology & Oncology Physician	$2.3M	$0
Robert Conry	AL	Hematology & Oncology Physician	$2.1M	$0
Lakshmikanth Katragadda	AL	Hematology & Oncology Physician	$2.1M	$0
Oncology Specialties, P.C.	AL	Hematology & Oncology Physician	$0	$2M
Surrinder Dang	AL	Hematology & Oncology Physician	$1.9M	$0

Nearby Providers

Other providers in the same ZIP code as Heather Brody, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Infants And Childrens Clinic PC	AL	Pediatrics Physician	$0	$8.7M
Shoals Pediatric Group PC	AL	Pediatrics Physician	$0	$4.4M
Pinnacle Medical Solutions LLC	AL	Durable Medical Equipment & Medical Supplies	$0	$4.4M
Stepping Stone Pediatric Therapy, Inc.	AL	Occupational Therapist	$0	$4.1M
Lifeguard Ambulance Service LLC	AL	Land Ambulance	$1.9M	$1.6M
Rchp - Florence LLC	AL	General Acute Care Hospital	$0	$3.4M
Alahealth, Inc.	AL	Case Management Agency	$0	$3.2M
Shoals Pediatric Dentistry, P.C.	AL	Pediatric Dentistry	$0	$3.1M
Shoals Hospice LLC	AL	Community Based Hospice Care Agency	$0	$3M
The Pediatric Dental Clinic	AL	Pediatric Dentistry	$0	$3M

Heather Brody — Billing Profile & Reimbursement Data

Sign up for Heather Brody — Billing Profile & Reimbursement Data policy alerts

Heather Brody — Billing Profile & Reimbursement Data

Sign up for Heather Brody — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References